Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec in Children With Refractory or Relapsed Solid Tumors
NCT00030667Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2002
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in Ewing sarcoma, primitive neuroectodermal tumor (PNET), osteosarcoma (OS) and 4 more, sponsored by National Cancer Institute. Primary endpoints: Response Rate up to 2 years and Toxicity up to 2 years. Started May 2002; status: completed.
02
Drugs
03
Conditions
Ewing sarcomaprimitive neuroectodermal tumor (PNET)osteosarcoma (OS)neuroblastomadesmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on NCT00030667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030667.